Study: Pfizer's Experimental Diabetes Drug Robustly Reduces Weight and Glucose

Data presented at the virtual American Diabetes Association meeting has Pfizer excited about the promise of its GLP-1R Agonist PF-06882961.

During a Monday presentation at the conference, Pfizer showcased Phase I data from a study assessing PF-06882961, an oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist in type 2 diabetes patients that showed significant promise in the reduction of glucose levels and body weight.